Tumor Mutational Burden as a Predictor of Response to Immunotherapy

A single definition of TMB as a predictor of survival benefit from immune checkpoint inhibitors across cancer types is not feasible, according to authors.

from Latest articles from Cancer Therapy Advisor News http://bit.ly/2TeVVZr